Robert Whitfield MDAmerica's Breast Implant Illness Expert™

Dr. Folkman's Cancer Breakthrough: The Anti-Angiogenesis Drugs #shorts

22 Oct 2025 · 1 min

Watch on YouTube

1:23

Robert Whitfield MD narrates an anecdote about Dr. Judah Folkman and his pioneering work on anti-angiogenesis drugs. Whitfield describes Folkman (identified here as a pediatric surgeon at Boston Children’s Hospital) presenting dramatic rodent experiments where tumors regressed after drugs that block blood-vessel growth, and links modern monoclonal antibody drugs ("mAb" suffix) back to Folkman’s lab. The tone is amazed and informal, emphasizing the perceived revolutionary nature of the work and its impact on oncology practice.

Questions this video answers

Pediatric surgeon at Boston Children’s Hospital.

"mAb" (monoclonal antibody).

Chapters

They rented a hotel across the street, and. And we're like, who the heck is Dr. Folkman? And so, Dr. Folkman, everybody, anytime you take a drug that has mAb at the end of it, it's because of Dr. Volkman. So all the people that show up telling me they. Their radiation oncologist or not, their. I'm sorry, their med doctor gave them XYZ mad. I'm like, yeah, that all came from judah folkman's lab. And he was a pediatric surgeon at boston children's hospital, and he came and presented his work, and it was crazy, doctor. It was absolutely effing crazy. He would show these little rodents. They would give them injections to give them cancer. They would get the tumor the size of a walnut on this little rodent, and then they'd give them the drug to block it and stop it and shrink it and go away. And everybody's like, is that real? Yeah. And so those are all of the antio angiogenesis drugs. And we're all like, this is some crazy stuff. We ever gonna have jobs? If you're. If you're sitting there, gonna be an oncologic surgeon, you're like, well, if this actually does work, tom, then we won't be doing much in the future. And everybody showed up for this talk.